EA201991464A1 - АНТИТЕЛО К α-СИНУКЛЕИНУ И ЕГО ПРИМЕНЕНИЕ - Google Patents

АНТИТЕЛО К α-СИНУКЛЕИНУ И ЕГО ПРИМЕНЕНИЕ

Info

Publication number
EA201991464A1
EA201991464A1 EA201991464A EA201991464A EA201991464A1 EA 201991464 A1 EA201991464 A1 EA 201991464A1 EA 201991464 A EA201991464 A EA 201991464A EA 201991464 A EA201991464 A EA 201991464A EA 201991464 A1 EA201991464 A1 EA 201991464A1
Authority
EA
Eurasian Patent Office
Prior art keywords
synuclein
aggregates
sinuclein
antibody
application
Prior art date
Application number
EA201991464A
Other languages
English (en)
Other versions
EA039807B1 (ru
Inventor
Чжинхён Ан
Сонвон Ан
Донин Ким
Ынсиль Сон
Джехён Ом
Сан Хун Ли
Сын-Джэ Ли
Тэ Кён Ким
Мин Сон Чой
Вонкю Ю
Джехо Чон
Джухи Ким
Джинвон Чон
Ёнчжу Ким
Ёнгю Сон
Бёндже Сон
Original Assignee
ЭйБиЭл БИО ИНК.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ЭйБиЭл БИО ИНК. filed Critical ЭйБиЭл БИО ИНК.
Priority claimed from PCT/KR2018/000239 external-priority patent/WO2018128454A1/ko
Publication of EA201991464A1 publication Critical patent/EA201991464A1/ru
Publication of EA039807B1 publication Critical patent/EA039807B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Psychology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

В настоящем изобретении раскрыты антитела к α-синуклеину, предпочтительно распознающие агрегаты α-синуклеина. Антитела по данному изобретению связываются с агрегатами α-синуклеина с высокой аффинностью и специфичностью и ингибируют накопление или внутриклеточный транспорт агрегатов α-синуклеина и, таким образом, могут использоваться для определения, диагностики и/или лечения или предупреждения различных заболеваний, вызванных накоплением агрегатов α-синуклеина.
EA201991464A 2017-01-06 2018-01-05 Антитело к -синуклеину и его применение EA039807B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762443151P 2017-01-06 2017-01-06
PCT/KR2018/000239 WO2018128454A1 (ko) 2017-01-06 2018-01-05 항 α-SYN 항체 및 그 용도
KR1020180001641A KR102014066B1 (ko) 2017-01-06 2018-01-05 항 α-syn 항체 및 그 용도

Publications (2)

Publication Number Publication Date
EA201991464A1 true EA201991464A1 (ru) 2020-01-15
EA039807B1 EA039807B1 (ru) 2022-03-16

Family

ID=63048162

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201991464A EA039807B1 (ru) 2017-01-06 2018-01-05 Антитело к -синуклеину и его применение

Country Status (7)

Country Link
US (1) US20230227540A1 (ru)
JP (1) JP6908709B2 (ru)
KR (1) KR102014066B1 (ru)
CN (1) CN110494445B (ru)
BR (1) BR112019013953A2 (ru)
EA (1) EA039807B1 (ru)
MX (1) MX2019008029A (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019117684A1 (ko) 2017-12-14 2019-06-20 에이비엘바이오 주식회사 a-syn/IGF1R에 대한 이중 특이 항체 및 그 용도
WO2020009551A1 (ko) 2018-07-06 2020-01-09 바이오그래핀 주식회사 신경단백질의 비정상적 섬유화 또는 응집과 관련된 질환 치료제로서의 그래핀 양자점
CN112368002B (zh) 2018-07-06 2023-05-30 生物石墨烯有限公司 用作与神经蛋白异常纤维化或凝聚相关疾病治疗剂的石墨烯量子点
EA202190807A1 (ru) * 2018-10-19 2021-08-06 Янссен Вэксинс Энд Превеншн Б.В. Антитела к синуклеину
EP3985022A4 (en) 2019-06-14 2023-08-02 ABL Bio, Inc. BISPECIFIC ANTIBODIES AGAINST A-SYN/IGF1R AND ITS USE
EP4379054A1 (en) 2021-07-27 2024-06-05 Stand Therapeutics Co., Ltd. Peptide tag and nucleic acid encoding same

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007001679A (es) * 2004-08-09 2007-05-23 Elan Pharm Inc Prevencion y tratamiento de la enfermedad sinucleinopatica y amiloidogenica.
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
SI2370466T1 (sl) * 2008-12-19 2015-11-30 Biogen International Neuroscience Gmbh Človeška avtoprotitelesa proti alfa-sinukleinu
PL2539366T3 (pl) * 2010-02-26 2018-06-29 Bioarctic Neuroscience Ab Przeciwciała wiążące protofibryle i ich zastosowanie w sposobach terapeutycznych i diagnostycznych w chorobie parkinsona, otępieniu z ciałami lewy'ego i innych alfa-synukleinopatiach
CN107091931A (zh) * 2011-11-02 2017-08-25 生物国际神经***科学公司 抗α‑共核蛋白抗体诊断脑中的α‑共核蛋白的升高水平的用途
EP4356927A2 (en) * 2012-10-12 2024-04-24 Arizona Board of Regents on behalf of Arizona State University Antibody based reagents that specifically recognize toxic oligomeric forms of tau
US9534044B2 (en) * 2013-02-28 2017-01-03 United Arab Emirates University Alpha-synuclein antibodies and uses thereof
EP3783020A1 (en) * 2013-11-21 2021-02-24 F. Hoffmann-La Roche AG Anti-alpha-synuclein antibodies and methods of use
US9629801B2 (en) * 2014-01-10 2017-04-25 Wisconsin Alumni Research Foundation Blood-brain barrier targeting antibodies
WO2016061389A2 (en) * 2014-10-16 2016-04-21 Genentech, Inc. Anti-alpha-synuclein antibodies and methods of use
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
EP3725802A4 (en) * 2017-11-17 2021-08-11 ABL Bio Inc. ANTIBODIES TO ALPHA SYNUCLEIN AND USES THEREOF
WO2019117684A1 (ko) * 2017-12-14 2019-06-20 에이비엘바이오 주식회사 a-syn/IGF1R에 대한 이중 특이 항체 및 그 용도

Also Published As

Publication number Publication date
CN110494445A (zh) 2019-11-22
JP2020515233A (ja) 2020-05-28
BR112019013953A2 (pt) 2020-02-11
KR20180081465A (ko) 2018-07-16
EA039807B1 (ru) 2022-03-16
KR102014066B1 (ko) 2019-10-21
US20230227540A1 (en) 2023-07-20
MX2019008029A (es) 2019-12-11
CN110494445B (zh) 2023-10-20
JP6908709B2 (ja) 2021-07-28

Similar Documents

Publication Publication Date Title
EA201991464A1 (ru) АНТИТЕЛО К α-СИНУКЛЕИНУ И ЕГО ПРИМЕНЕНИЕ
EA202090104A1 (ru) Молекулы антител к cd73 и пути их применения
EA201890712A1 (ru) Антитела к про-/латентному миостатину и их применения
EA201892417A1 (ru) Антитела, распознающие тау
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
EA202091540A1 (ru) Антитела к lilrb2
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
AR101846A1 (es) Anticuerpos anti-cll-1 e inmunoconjugados
EA201992546A1 (ru) Средства на основе антител к cd33
EA202092435A3 (ru) Моноклональные антитела против bcma
EA201790984A1 (ru) Анти-cd79b антитела и способы их применения
EA201591716A1 (ru) Антитела анти-il-33 и их применение
EA201691488A1 (ru) Молекулы антител против pd-1 и их применения
EA201791093A1 (ru) Антитела к cd47, способы и применение
EA201692539A1 (ru) Антитела и антигенсвязывающие фрагменты, которые специфично связываются с белком тау, ассоциированным с микротрубочками
PE20170665A1 (es) Anticuerpos anti-tau humanizados
EA201992091A1 (ru) Анти-c5 антитела и их применение
EA201591750A1 (ru) Антитела против b7-h4 и иммуноконъюгаты
EA201691556A1 (ru) Молекулы антител к tim-3 и их применение
EA201892412A1 (ru) Антитела, распознающие тау
EA201691610A8 (ru) Анти-jagged1 антитела и способы применения
PE20161032A1 (es) Anticuerpos anti-tau(ps422) humanizados y metodos de utilizacion
MX2020004674A (es) Anticuerpos contra alfa-sinucleina y usos de los mismos.
EA201792220A1 (ru) Опосредуемая антителом нейтрализация вируса чикунгунья
NZ730186A (en) Humanized anti-hepcidin antibodies and uses thereof